<html>
<head>PUBMED IDs for AMOTL2</head>
<body bgcolor='#C5F0F2'><h1>AMOTL2</h1><a href='https://pubmed.ncbi.nlm.nih.gov/21187284/'>Angiomotin-like proteins associate with and negatively regulate YAP1.</a> March 25  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/21205866/'>Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein.</a> January 28  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/21937427/'>Angiomotin-like2 gene (amotl2) is required for migration and proliferation of endothelial cells during angiogenesis.</a> January 17  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/22385262/'>The Nedd4-like ubiquitin E3 ligases target angiomotin/p130 to ubiquitin-dependent degradation.</a> July 14  2012<br><a href='https://pubmed.ncbi.nlm.nih.gov/23911299/'>AMOTL2 interaction with TAZ causes the inhibition of surfactant proteins expression in lung cells.</a> November 13  2013<br><a href='https://pubmed.ncbi.nlm.nih.gov/25998128/'>Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth and Invasiveness.</a> November 6  2015<br></body></html>
